Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy

(1) Background: Chronic pain is one of the most common reasons for individuals to seek medications. Historically, opioids have been the mainstay of chronic pain management. However, in some patient populations, opioids fail to demonstrate therapeutic efficacy, whereas in other populations, opioids m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feng-Hua Loh, Brigitte Azzi, Alexander Weingarten, Zvi G. Loewy
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	pain pharmacogenomics polymorphism pharmacotherapy Medicine R
Acceso en línea:	https://doaj.org/article/209b9af25ce8407883de29e7c427511f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:209b9af25ce8407883de29e7c427511f
record_format	dspace
spelling	oai:doaj.org-article:209b9af25ce8407883de29e7c427511f2021-11-25T18:07:17ZPharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy10.3390/jpm111111122075-4426https://doaj.org/article/209b9af25ce8407883de29e7c427511f2021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1112https://doaj.org/toc/2075-4426(1) Background: Chronic pain is one of the most common reasons for individuals to seek medications. Historically, opioids have been the mainstay of chronic pain management. However, in some patient populations, opioids fail to demonstrate therapeutic efficacy, whereas in other populations, opioids may cause toxic effects, even at lower doses. Response to pain medication is affected by many factors, including an individual’s genetic variations. Pharmacogenomic testing has been designed to help achieve optimal treatment outcomes. This study aimed at assessing the impact of CYP2D6 pharmacogenomic testing on physicians’ choice in prescribing chronic pain medications and patient pain control. (2) Methods: This retrospective study reviewed 107 patient charts from a single site pain management center. All 107 patients received pharmacogenomic testing. The outcomes of interest were confirmation that the optimal pain medication is being administered or a change in the chronic pain medication is warranted as a result of the pharmacogenomic testing. The main independent variable was the pharmacogenomic test result. Other independent variables included patient gender, race, and comorbidities. The retrospective study was reviewed and approved by the Touro College and University System IRB, HSIRB1653E. (3) Results: Patients self-reported pain intensity on a scale of 1–10 before and after pharmacogenomic testing. Then, 100% of patients in the retrospective study were tested for their pain pharmacogenomic profile. Of the 107 patients participating in the study, more than 50% had their medications altered as a result of the pharmacogenomic testing. The percentage of patients with intense pain were decreased post-pharmacogenomic testing (5.6%) as compared to pre-pharmacogenomic testing (10.5%). Patients with intense, moderate, and mild pain categories were more likely to receive changes in pain medications. In contrast, patients with severe pain were less likely to receive a change in pain medication. Hispanic ethnicity was associated with a statistically significantly decrease in a pain scale category. Illegal drug abuse was associated with a decrease in pain scale category. Change in medication dose was associated with a decrease in pain scale category. (4) Conclusion: In this retrospective study, implementation of pharmacogenomic testing demonstrated significant benefits to patients with intense pain undergoing treatment.Feng-Hua LohBrigitte AzziAlexander WeingartenZvi G. LoewyMDPI AGarticlepainpharmacogenomicspolymorphismpharmacotherapyMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1112, p 1112 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pain pharmacogenomics polymorphism pharmacotherapy Medicine R
spellingShingle	pain pharmacogenomics polymorphism pharmacotherapy Medicine R Feng-Hua Loh Brigitte Azzi Alexander Weingarten Zvi G. Loewy Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy
description	(1) Background: Chronic pain is one of the most common reasons for individuals to seek medications. Historically, opioids have been the mainstay of chronic pain management. However, in some patient populations, opioids fail to demonstrate therapeutic efficacy, whereas in other populations, opioids may cause toxic effects, even at lower doses. Response to pain medication is affected by many factors, including an individual’s genetic variations. Pharmacogenomic testing has been designed to help achieve optimal treatment outcomes. This study aimed at assessing the impact of CYP2D6 pharmacogenomic testing on physicians’ choice in prescribing chronic pain medications and patient pain control. (2) Methods: This retrospective study reviewed 107 patient charts from a single site pain management center. All 107 patients received pharmacogenomic testing. The outcomes of interest were confirmation that the optimal pain medication is being administered or a change in the chronic pain medication is warranted as a result of the pharmacogenomic testing. The main independent variable was the pharmacogenomic test result. Other independent variables included patient gender, race, and comorbidities. The retrospective study was reviewed and approved by the Touro College and University System IRB, HSIRB1653E. (3) Results: Patients self-reported pain intensity on a scale of 1–10 before and after pharmacogenomic testing. Then, 100% of patients in the retrospective study were tested for their pain pharmacogenomic profile. Of the 107 patients participating in the study, more than 50% had their medications altered as a result of the pharmacogenomic testing. The percentage of patients with intense pain were decreased post-pharmacogenomic testing (5.6%) as compared to pre-pharmacogenomic testing (10.5%). Patients with intense, moderate, and mild pain categories were more likely to receive changes in pain medications. In contrast, patients with severe pain were less likely to receive a change in pain medication. Hispanic ethnicity was associated with a statistically significantly decrease in a pain scale category. Illegal drug abuse was associated with a decrease in pain scale category. Change in medication dose was associated with a decrease in pain scale category. (4) Conclusion: In this retrospective study, implementation of pharmacogenomic testing demonstrated significant benefits to patients with intense pain undergoing treatment.
format	article
author	Feng-Hua Loh Brigitte Azzi Alexander Weingarten Zvi G. Loewy
author_facet	Feng-Hua Loh Brigitte Azzi Alexander Weingarten Zvi G. Loewy
author_sort	Feng-Hua Loh
title	Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy
title_short	Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy
title_full	Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy
title_fullStr	Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy
title_full_unstemmed	Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy
title_sort	pharmacogenomic testing and patient perception inform pain pharmacotherapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/209b9af25ce8407883de29e7c427511f
work_keys_str_mv	AT fenghualoh pharmacogenomictestingandpatientperceptioninformpainpharmacotherapy AT brigitteazzi pharmacogenomictestingandpatientperceptioninformpainpharmacotherapy AT alexanderweingarten pharmacogenomictestingandpatientperceptioninformpainpharmacotherapy AT zvigloewy pharmacogenomictestingandpatientperceptioninformpainpharmacotherapy
_version_	1718411604737916928

Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy

Ejemplares similares